Amidines

ABSTRACT

N-Aralkyl-aryl or aralkylcarboxamidines, e.g., those of the formula   Ar1,2 isocyclic aryl R1,2 H, alkyl or aralkyl M 1-7, N 0-4, P 1 OR 2 AND SALTS THEREOF EXHIBIT DIURETIC AND HYPOGLYCEMIC EFFECTS.

United States Patent Rodriguez et al.

[ Jan. 21,1975

AMIDINES Inventors: Herman Robert Rodriguez, New

York, N.Y.; George De Stevens, Summit, NJ.

Assignee: Ciba-Geigy Corporation, Ardsley,

Filed: Feb. 18, 1972 Appl. No.: 227,619

Related US. Application Data Continuation-impart of Ser. No. 10,649, Feb. 11, 1970, abandoned, which is a continuation-in-part of Ser. Nos. 704,517, Feb. 12, 1968, Pat. No. 3,681,340, and Ser. No. 649,828, June 29, I967, abandoned, said Ser. No. 704,517, and Ser. No. 649,828; each is a continuation-in-part of Ser. No. 630,520, April 13, 1967, abandoned.

Int. C1,. ..C07c 123/00 Field of Search ..260/564 R, 556 AR, 260/343.7,501.11,501,1u955 S,

[56] References Cited UNITED STATES PATENTS 2,450,386 9/1948 Short et al. 260/564 R FOREIGN PATENTS OR APPLICATIONS v 642,286 8/1950 Great Britain 260/564 OTHER PUBLICATIONS Chemical Abstr., Vol. 47, Column lll56(e), (Partridge et al.), 1953.

Primary Examiner-Bernard Helfin Assistant Examiner-Gerald A. Schwartz Attorney, Agent, or Firm-Joseph G, Kolodny; John Jv Maitner; Theodore O. Groeger [57] ABSTRACT N-Aralkyl-aryl or aralkylcarboxamidines, c,g., those of the formula Ar isocyclic aryl R H, alkyl or aralkyl and salts thereof exhibit diuretic and hypoglycemic effects.

6 Claims, No Drawings AMIDINES CROSS-REFERENCES TO RELATED APPLICATIONS This is a continuation-in-part of application Ser. No. 10,649, filed Feb. 11, 1970 now abandoned, which in turn is a continuation-in-part of application Ser. No. 704,517, filed Feb. 12, 1968, now Pat. No. 3.681.340 and of Ser. No. 649,828, filed June 29, 1967 now aban doned, both of which latter are continuations-in-part of application Ser. No. 630,520, filed Apr. 13, 1967, now abandoned.

SUMMARY OF THE INVENTION The present invention concerns and has for its object the provision of new N-aralkyl-aryl or aralkylcarboxamidines, more particularly of those corresponding to Formula I m Em' DESCRIPTION OF THE PREFERRED EMBODIMENTS A monocyclic isocyclic aryl radical Ar and Ar, is phenyl or phenyl substituted by one or more than one, preferably up to three, of the same or different substituents attached to any of the positions available for sub stitution. Such substituents are, for example, lower alkyl, e.g., methyl, ethyl, nor i-propyl or -butyl, free, etherified or esterified hydroxy, mercapto, or hydroxylower alkyl, such as lower alkoxy, alkylenedioxy, aralkoxy, alkylmercapto, e.g., methoxy, ethoxy, nor ipropoxy or -butoxy; methylenedioxy, l,lor 1,2- ethylenedioxy; benzyloxy; methylor ethylmercapto;

- hydroxymethyl; halogeno, or halogeno-lower alkyl,

e.g., fluoro, chloro or bromo; chloromethyl or trifluoromethyl; nitro, amino, di-lower alkylamino or lower alkanoylamino, e.g., dimethylamlno or diethylamino; acetylamino or propionylamino; free, esterified or amidated carboxy or sulfo, such as carbo-lower alkoxy, e.g., carbomethoxy or carbethoxy, or di-lower alkylsulfamyl, e.g., dimethylsulfamyl. Preferred radicals Ar, and Ar, stand for phenyl, (lower a1kyl),- phenyl, (hydroxy)-phenyl, (lower a]koxy),- -phenyl, (lower alkylenedioxy)-phenyl, (lower alkylmercapto)-phenyl, (halogeno),- -phenyl, (trifluoromethylyphenyl, (nitro)-phenyl, (amino)-phenyl, (di-lower alkylamino)- phenyl, (lower alkanoylamino)-phenyl, (carboxy)- phenyl, (carbo-lower alkoxy)-phenyl or (sulfamoyl)- phenyl, and Ar also for (lower alkyl or alkoxy) -halophenyl, (lower alkyl or alkoxy) -nitrophenyl or (lower alkyl or alkoxy), -sulfamoylphenyl.

A lower alkyl group R, and R is, for example such mentioned above. An aralkyl group R and R is preferably unsubstituted or substituted aryl-lower alkyl, e.g., one of the mono-substituted radicals Ar C,,,H mentioned above. An amino group R is unsubstituted, monoor disubstituted by lower alkyl. As used above and hereinafter the term lower in connection with hydrocarbon radicals defines such with up to seven, preferably up to four, carbon atoms.

The lower alkylene group C H represents preferably 1,2-ethylene, but also methylene, 1,1-ethylene, 1,2- or 1.3-propylene, 1.2-. 1,3- 2,3- or 1.4-lmtylcne. 1,2. 1,3-,2,3- or 2,4pentylene, 1,2- 1,3-, 1,4-. 2,3-. 2,4or 3,4-hexylene, 2,6- or 3,4-heptylene. The group C,,H preferably represents a direct bond but also alkylene with up to four carbon atoms, e.g., such previously mentioned, particularly methylene.

The compounds of the invention exhibit valuable pharmacological properties. Apart from diuretic effects, they show primarily hypoglycemic activity, as can be demonstrated in animal tests, using mammals, for example, mice, rats or dogs as test objects. The compounds of the invention can be administered cnterally or parenterally, advantageously orally to the animals, e.g., to dogs at a dose between about 1 and 10 mg/kg/day, or to normal, fasted, water or glucose primed or adrenalectomized rats at a dose between about 10 and 200 mg/kg/day, preferably between about 25 and mg/kg/day, whereupon their urine or orbital blood is collected and analyzed. Accordingly, the com pounds of the invention are either valuable hypoglycemic agents, especially in the higher dosage range between about 5 and 50 mg/kg/day, or useful diuretics, advantageously in the lower dosage range between about 1 and 25 mg/kg/day. Both of said activities are desirable due to the fact that several diuretics induce hyperglycemia. Said compounds are also useful intermediates of other valuable products, e.g., those described in the above-mentioned parent applications.

Particularly useful are compounds of the Formula I, in which each of Ar, and Ar is phenyl, (lower alkyl)- -phenyl, (hydroxy)-phenyl. (lower alkoxy),;,- phenyl, (lower alkylenedioxy)-phenyl, (lower alkylmercapto)-phenyl, (halogeno),- -phenyl, (trifluoromethyl)-phenyl, (nitro)-phenyl, (amino)-phenyl, (di-lower alkylamino)-phenyl, (lower alkanoylamino)- phenyl, (carboxy)-phenyl, (carbo-lower alkoxy)- phenyl or (sulfamoyl)-phenyl, Ar also is (lower alkyl or alkoxy), -halophenyl, (lower alkyl or alkoxylmnitrophenyl or (lower alkyl or alkoxy), sulfamoylphenyl, m is an integer from 1 to 7, n is an integer from 0 to 4,! is the integer l or 2. each of R. and R is hydrogen or lower alkyl and, in case p is l, R, also is amino, lower alkylamino or di-lower alkylamino, or therapeutically useful acid addition salts thereof.

Preferred compounds are those of Formula II R alk- III- (If C H R wherein R is phenyl, (lower alkyl),- -phenyl, (hydroxy)-phenyl, (lower alk0xy) -phenyl, (halogenohphenyl, (trifluoromethyl)-phenyl, (nitro)-phenyl, (dilower alkylamino)-phenyl, (carboxy)-phenyl or (carbo-lower alkoxy)-phenyl, n is the integer 0 or 1, each of R and R, is hydrogen or lower alkyl, R is hydrogen, lower alkoxy, halogeno, nitro or sulfamoyl, each of R and R is hydrogen, lower alkyl or lower alkoxy, and alk is lower alkylene separating the benzene nucleus from the nitrogen atom by one to three carbon atoms, or therapeutically useful acid addition salts thereof, i.e., salts of pharmaceutically acceptable acids.

Compounds that are especially valuable are those of Formula [II R N-R in which each of R and R is hydrogen or methyl, alk is alkylene with two to four carbon atoms separating the benzene nucleus from the nitrogen atom by two carbon atoms, n is the integer O or 1, R is hydrogen, methoxy, chloro, nitro or sulfamoyl, one of R R and R is hydrogen and the others, as well as R and R are hydrogen, methyl, ethyl, isopropyl, methoxy, ethoxy or isobutoxy, or each of R and R are also hydroxy, chloro, trifluoromethyl, nitro, amino or carboxy, or therapeutically useful acid addition salts thereof.

Most important are those compounds of Formula [II in which each of R R and R is hydrogen, alk is 1,2- ethylene, 1,2-propylene or 1,2-butylene, n is the integer 0, R is hydrogen, methoxy, chloro, nitro or sulfamoyl, each of R and R is methoxy and each of R' and R is hydrogen, methyl or chloro, or therapeutically useful acid addition salts thereof which, when given at oral doses between about 1 and 50 mg/kg/day to normal, fasted, glucose primed or adrenalectomized rats, show outstanding diuretic and hypoglycemic effects.

The compounds of the invention are prepared according to methods in themselves known, for example, the corresponding process consists in a. condensing a reactive functional derivative of an arylor aralkylcarboxylic acid with a primary or secondary aralkylamine, preferably compounds of the formulae in which X stands for and Y for a reactively converted, nitrogen containing carboxyl group or X for reactively esterified hydroxy or mercapto and Y for N-R n 2 b. reacting an N-aralkyl derivative of a nitrogen containing, reactive functional derivative of an arylor aralkylcarboxylic acid with an amine, preferably compounds of the formulae R Z l u such, derived from lower alkanols or cyano-alkanols. A reactive functional derivative of the carboxylic acid used in reaction (a) is, for example, its imido ester, imido thioester, unsubstituted amidine or nitrile.

(III) Any compound so-obtained, containing in the aromatic portion a substituent convertible into such spe cifically mentioned above, e.g., an azo group, such group may be converted into amino, for example by hydrogenation, advantageously in an acidic medium. Also the compounds of the invention may be converted intoeach other by known methods. Thus, for example, resulting compounds containing free hydroxy, mercapto or amino groups, may be etherified, esterified or N- substituted, for example with the use of reactive esters of corresponding alcohols derived, for example, from the acids mentioned above, or with reactive functional acid derivatives, e.g., the halides or anhydrides. Resulting nitro compounds may be reduced as shown for the azo compounds and acylamino compounds hydrolyzed.

The above-mentioned reactions are carried out according to standard methods, in the presence or absence of diluents, preferably such as are inert to the reagents and are solvents thereof, of catalysts, condensing agents and/or inert atmospheres, at low temperatures, room temperature or elevated temperatures, at atmospheric or superatmospheric pressure.

The compounds of the invention are obtained in the free form or in the form oftheir salts, depending on the conditions under which the process is carried out; the salts are also included in the present invention. Salts that are obtained can be converted into the free bases in known manner, for example, with alkalis or ion exchangers. Free bases that are obtained can be converted into salts by reaction with inorganic or organic acids, especially those that are suitable for the formation of therapeutically useful salts. Such acids are, for example, hydrohalic acids, e.g., hydrochloric or hydrobromic acid, sulfuric, phosphoric, nitric or perchloric acid, aliphatic, alicyclic, araliphatic, aromatic or heterocyclic carboxylic or sulfonic acids, for example, formic, acetic, propionic, succinic, glycollic, lactic, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, pyroracemic, phenylacetic, benzoic, aminobenzoic, anthranilic, 4-hydroxybenzoic, salicylic, aminosalicylic, embonic, nicotinic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, ethylenesulfonic, halogenbenzenesulfonic, toluenesulfonic, naphthalenesulfonic or sulfanilic acid; methionine, tryptophan, lysine or arginine.

These or other salts, for example, the picrates, can also be used for the purification of the bases obtained; the bases are converted into salts, the salts are separated and the bases are liberated from the salts. in view of the close relationship between the free compounds and the compounds in the form of their salts, whenever a free base is referred to in this context, a corresponding salt is also intended, provided such is possible or appropriate under the circumstances.

The invention further includes any variant of the present process, in which an intermediate product 0btainable at any stage of the process is used as starting material and any remaining steps are carried out, or the process is discontinued at any stage thereof, or in which the starting materials are formed under the reaction conditions, or in which the reaction components are used in the form of their salts. For example, amines, alcohols or phenols may be used in the form of the alkali or alkaline earth metal salts, e.g., sodium potassium, magnesium, halomagnesium or clacium salts, and the nitrogen containing acid derivatives, e.g., imidic acid esters, in the form of their acid addition salts. Mainly, those starting materials should be used in the above reactions that lead to the formation of those compounds indicated as being specially valuable.

The starting material used is known or, if new, may be prepared according to known methods, e.g., the classical amination or amidation reactions, described, for example, by R. B. Wagner and H. D. Zook in Synthetic Organic Chemistry John Wiley & Sons, Inc., New York, 1956, or according to the following new nitration method, which is a further object of the present invention.

The new method for the preparation of o-nitroaralkanes containing in the alkyl chain a group capable of forming a nitrate, such as a basic nitrogen containing group, e.g., prim., sec. or tert. amino, hydrazino, imino or hydrazono, free or etherified hydroxyamino or oximino, amidino, guanidino and the like, the corresponding quaternary and/or hydrogenated forms, which process consists in subjecting a nitrate of an ortho-unsubstituted aralkane containing in the alkyl chain said group capable of forming a nitrate, to pyrolysis, advantageously under acidic conditions.

Accordingly, starting material used in the process of the invention can be prepared by subjecting a compound of the formula Ar -C H in which Ar is an isocyclic aryl radical, e.g., such mentioned above, containing in at least one of the ortho positions a hydrogen atom, to acidic conditions and/or an elevated temperature. Generally any relatively strong The pharmacologically active compounds of the invention are useful in the manufacture of pharmaceutical compositions containing an effective amount thereof in conjunction or admixture with excipients suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredient together with (a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine, (b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol, for tablets also (c) binders, e.g., mangesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, if desired, ((1) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, enzymes of the binders or effervescent mixtures and/or (e) adsorbents, colorants, flavors and sweeteners. lnjectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously fatty emulsions or suspensions. They may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. Said pharmaceutical compositions may also contain other therapeutically valuable substances. They are prepared according to conventional mixing, granulating or coating methods respectively and contain about 0.] to 75 percent, preferably about 1 to percent, of the active ingredient.

The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees Centigrade, and all parts wherever given are parts by weight.

EXAMPLE I To the solution of 25 g 2-(2-nitro-4,5-dimcthoxyphenyl)-ethylamine in 500 ml dimethylformamide, 22.5 g 4-methyl-benzimidic acid ethyl ester hydrochloride are added and the mixture heated overnight to 80 while stirring. It is then evaporated, the residue triturated with acetone and diethyl ether and recrystallized from methanol-ethanol to yield the N'[2-(2-nitro-4,5-

acid may be used, hydrochloric and trifluoroacetic acid 45 dimethoxy-phenyl)-ethyl]-4-methyl-benzamidine hyare particularly useful. The temperature range for this drochloride of the formula C H CH3O 2 NH- 0 ea HCl iia CH O NO reaction is about 0 to 200, preferably about 20 to melting at 223"225. 100. The starting material is prepared as follows: The solu- Starting materials or final products that are mixtures tion of 190 g 2-(3,4-dimethoxy-phenyl)-ethylamine in of isomers can be separated into single isomers by 2 liters isopropanol is neutralized by the dropwise addimethods in themselves known. For example, comtion of concentrated nitric acid while stirring and coolpounds that contain one or more asymmetrical carbon ing in an ice bath. The precipitate formed is filtered off, atom ay b i t e form o racemate ixt pu e washed with isopropanol and diethyl ether and dried to racemates or optical antipodes. Mixtures of racemates, yield the corresponding nitrate melting at l52l54 by virtue of the physicochemical differences between (d the Components, can be resolved into P racemates, 240 g thereof are added portionwise to 1 liter trifluofor p y Chromatography and/0r fractional roacetic acid while stirring, whereby the temperature is cryslillllzillllm- Rllumlc Pmducts can likewisc he allowed to rise to about H ereupon the mixture is solved into the optical antipodes, for example, by reaction with optically active acids, separation of the diastereomeric salts and liberation of the bases from the salts.

evaporated in vacuo, tje residue dissolved in 1.5 liter ethyl acetate and the solution acidified with saturated hydrogen chloride in ethyl acetate. The precipitate formed is filtered off, washed with ethyl acetate and diethyl ether and recrystallized from ethanol, to yield the and Washed With diethy ether o yi l e 2-(2-nitro-4,5-dimethoxy-phenyl)-ethylamine hydro- 4-trifluoromethyl-benzimidic acid'ethyl ester hydrochloride melting at 240. It is dissolved in the minimum Chloride melting at amount of water, the solution made strongly basic with In the analogous fi the foll ng new Slilrling aqueous potassium hydroxide, the mixture extracted m te als are prepared:

with chloroform, the extract dried, filtered and evapoa. 4-ethyl-benzimidic acid ethyl ester hydrochloride,

rated to yield the corresponding base which melts, after m.p. 1 13-l 14.

recrystallization from diethyl ether, at 104-108. b. 4-isopropyl-benzimidic acid ethyl ester hydrochlo- In the analogous manner, the following new starting ride, m.p. l -1 1 1.

materials are prepared: 10 c. 4-tolyl-acetimidic acid ethyl ester hydrochloride,

a. 2-(2-nitro-4,5-diethoxy-phenyl)-ethylamine hym.p. 133.

drochloride, m.p. 222-224. b. 3-(2-nitro--4,5-dimethoxy-phenyl)-propylamine EXAMPLE4 hydrochl ri e, -P- To the solution of 3.1 g 2-(2-nitro4,5-diisobutoxyl5 phenyl)-eth lamine in 100 ml dimethylformamide, 2.1 EXAMPLE 2 g 4-methylbenzimidic acid ethyl ester hydrochloride T0 the Solution 0f 10 g l P YU- are added and the mixture stirred overnight at 80. lt ethylamine in 500 ml tetrahydrofuran, 9.3 g is then evaporated in vacuo, the residue triturated with N-methyl-4-methyl-benzimidoyl chloride are added acetone and diethyl ether and recrystallized from etha dropwise while stirring and the mixture is heated at the no], to yield the N-[2-(2-nitro-4,5-diisobutoxy-phenyl) steam bath for one-half an hour. It is cooled, the preethyl]-4-methylbenzamidine hydrochloride of the forcipitate formed filtered off, washed with tetrahydromula (CH C H O C H ll .HCl NH CH CH -C H O No I 3 furan and recrystallized from ethanol-isopropanol to showing in the IR. spectrum, inter alia bands at 1,612 yield the N-methyl-N'-[2-(3,4-dimethoxy-phenyl)- and 1,668 ethyl]-4-methyl-benzamidine hydrochloride f h f The starting material is prepared as follows: To the mula 1 mixture of 38 g ofa percent sodium hydride suspen- CH O C H 3 2 NH'C ca HCl N CH CH O 3 melting at l88-193. sion in mineral oil and 200 ml dimethylsulfoxide, the solution of 55.2 g 3,4-dihydroxy-benzaldehyde in 400 EXAMPLE 3 g ml dimethylsulfoxide is added dropwise while cooling and stirring. The mixture is then heated on the steam To the Solunon of g l" bath and g isobutyl' bromide are added dropwise 45 phenyn'ethylamme m 100 m] ethanol 8 while stirring, and stirring is continued overnight at the 4-trifluoromethyl-benzimidic acid ethyl es hydro' steam bath. After cooling, the mixture is diluted with chloride are added and the whole 18 stirred and refluxed Water, extracted with diethyl ether, the extract washed for 16 hours. The mixture is evaporated in vacuo, the with 0 percent aqueous Sodium hydroxide and Waterv residue trlturatel with ethyl and rec'rystalhzed 5O dried, filtered and evaporated. The residue is distilled from ethanol to W the -l l and the fraction boiling at l49l55/0.06-0.07 mm Hg P y ly l' y y collected. lt solidifies on standing and is recrystallized Chloride of the formula from hexane to yield the 3,4-diisobutoxy-benzaldehyde CH 0 C H 3 2 NH-CO CF c ll 3 NH CH O NO melting at 200202. melting at 4042.

The new starting material is prepared as follows: To The mixture of48 g thereof, 15 g ammonium acetate, the solution of g 4-trifluoromethyl-benzonitrile in 16 ml nitromethane and 150 ml acetic acid is refluxed 700 ml anhydrous diethyl ether, 75 ml anhydrous ethafor 2 hours. After cooling the precipitate formed is filnol are added and dry hydrogen chloride is bubbled 65 tered offand washed with acetic acid and water to yield through the stirred mixture at 0 until saturation is the B-nitro-3,4diisobutoxy-styrene, melting at reached. Upon addition of diethyl ether to a small sam- 122-l24. ple, some crystals are obtained, which are used to seed The solution of 40 g thereof in 500 ml tetrahydro the main batch; the latter is allowed to stand overnight furan is added dropwise to the mixture of 16 g lithium in the refrigerator. The precipitate formed is filtered off aluminumhydride in 300ml diethyl ether while stirring.

Hereupon the mixture is stirred for an additional hour tion of the theoretical amount of hydrogen, the mixture and the excess reducing agent decomposed with water. is filtered, the filtrate acidified with ethanolic hydro- The mixture is filtered, the residue washed with tetrachloric acid, the solution combined with the equal volhydrofuran and the filtrate evaporated to yield the 2- ume ofdiethyl ether and the precipitate formed filtered (3,4-diisobutoxy-phenyl)-ethylarnine as an oil. 5 off: it represents the N-[2-(2-amino-4.5-dimethoxy- The solution of 38 g thereof in 200 ml ethanol is neuphenyl)-ethyl]-benzamidine dihydrochloride of the fortralized by the dropwise addition of concentrated nitric mula CH C C H 3 2 t Nn c ZHCl NH CH 0 NH acid. It is then evaporated, the residue dissolved in the melting at 274.

minimum amount of diethyl ether and upon stirring in the cold a precipitate separates, which is filtered off EXAMPLE 6 and dissolved in 100 ml trifluoroacetic acid. The solu- To the solution of 15 g 2-(2-nitro-4,5-dimcthoxytion is heated on the steam bath for 15 minutes, then phenyl)-ethylamine in 100 ml methanol, 13 g evaporated and the residue triturated with diethyl ether phenylacetimidic acid ethyl ester hydrochloride are I0 yiel the 2-(2- i r0- ,5- 0xy-phenyl)- added and the mixture is refluxed for 5 hours. It is.

ethylamin IrifluOrOaCelate, melting at It is cooled and the precipitate formed filtered off to yield dissolved in the minimum amount of water, the solution th N [2-(Z-nitm 4,5-dimeth0x -phen |)-ethyl made basic with aqueous sodium hydroxide, extracted phenylacetamidine hydrochloride of the formula CH C NO with tetrahydrofuran and the extract evaporated to melting at 220222.

'ield the corres ondin free base. y p g EXAMPLE 7 The mixture of 5.0 g N-methyl-2-(2-nitro-4,5-dimethoxy-phenyl)-ethylamine, 3.9 g ethyl benzimidate-hy- EXAMPLE 5 drochloride and 25 ml ethanol is refluxed for 17 hours. The mixture of 80 g 2-(2-nitro-4,5-dimethoxy- It is then evaporated, the residue triturated with ethyphenyl)-ethylamine, 66 g benzimidic acid ethyl ester lacetate and then with chloroform to yield, after filtrahydrochloride and 750 ml methanol is refluxed for 3 tion, the N-methyl-N-[2-(2-nitro-4,5-dimethoxyhours, then concentrated to 250 ml and the concenphenyl)-ethyl]-benzamidine hydrochloride of the fortrate diluted with 1.5 liter diethyl ether. The yellow mula CH 7 CH O c a 1!I 3 C H01 NH on o M0,, 3

precipitate formed is filtered off and washed with dimelting at 2l8219. ethyl ether to yield the N-[2-(2-nitro-4,5-dimethoxyphenyl)-ethyl]-benzamidine hydrochloride melting at EXAMPLE 8 235--239. In the manner described in the previous Examples,

g thereof are dissolved in 1 liter methanol and hythe following compounds of Formula [II are prepared drogenated at an initial pressure of 40 psi. over 2 g from equivalent amounts of the corresponding starting platinum oxide at room temperature. After consumpmaterials; R =R =H:

No. R; R, R; R; R R m n Salt m.p.C Recr.from

l H H H H H H 2 O HC1 164-170 1C;H-,OH 2 H H H H CH; H 2 HC1 259-261 C,H;OH 3 H H OCH; H CH; H 2 0 HC1 229-232 i-C;H;OH 4 H OCH; H H CH; H 2 O HC1 192-195 iC;H OH 5 H CH; CH; H CH; H 2 0 HC1 249-252 C;H;OH 6 H OCH; OCH; H H H 2 0 HC1 198-200 C;H;OH 7 H OCH; OCH; H CH; H l 0 HC1 136-140 C H;OH 8 H OCH; OCH; H CH; H 2 0 HC1 209-210 C;H;OH 9 H OCH; OCH; H CH; H 3 0 HC1 204-206 C H;OH 10 H OCH; OCH; H CH; H l 1 HC1 164-166 iC;H;OH 11 H OCH; OCH; H C;H; H 2 0 HC1 212-214 C;H;OH 12 H OCH; OCH; H iC;H; H 2 0 HC1 179-180 iC;H;OH 13 H OCH; OCH; H NO; H 2 0 HCI 227-229 iC;H;OH 14 H OCH; OCH; H NH; H 2 0 2HC1 230-233 iC;H OH 15 H OC;H; OC;H; H CH; H 2 0 HC1 205-206 C;H;OH 16 H H OCH;-O CH; H 2 0 HC1 245-248 C;H;OH 17 OCH; OCH; H H CH; H 2 O HC1 194-195 iC;H OH l8 OCH; H OCH; H CH; H 2 0 HC1 176-178 i-C;H;OH 19 OCH; H H OCH; CH; H 2 0 HC1 191-195 i-C;H;OH 20 H C1 C1 CH; H 2 0 HC1 265-268 C H;OH 21 C1 H OCH; OCH; CH; H 2 0 HC1 237-239 C;H;0H 22 OCH; H OCH; OCH; CH; H 2 0 HC1 218-220 i-C;H;OH 23 NO; H OCH; OCH; H H 2 0 HC1 241-243 CH;OH 24 NH; H OCH; OCH; H H 2 0 2HC| 276-278 C.;H;OH 25 NH; H OCH; OCH; CH; H 2 0 2HC1 285-287 CH;OH 26 NO; H OCH; OCH; H CH; 2 0 HC1 207-211 i-C;H-,OH 27 NO; H OCH; OCH; CH; CH; 2 O HC1 236-238 iC;H;OH 28 NO; H OCH; OCH; OCH; H 2 0 HC1 200 C;H;OH 29 NH; H OCH; OCH; OCH; H 2 0 2HCI 281-283 CH;OH 30 NO; H OCH; OCH; Cl H 2 0 HC1 235-239 C-;H;OH 31 NO; H OCH; OCH; CH; H 3 0 HC1 200-203 i-C;H;OH 32 N0 H OCH; OCH; CH; H 2 l HC1 219-220 CH;OH 33 NO; H OCH; OCH; iC;H, H 2 0 HC1 197-199 CH;CN 34 NO; H OCh; OCH; COOH H 2 0 HCI 254-255 iC;H;OH 35 N0 H OC;H; OC;H; CH; H 2 0 HC1 210-212 C,H ,oH 36 H OCh; OCH; OCH; CH; H 2 0 HC1 229-232 iC;H;OH

EXAMPLE 9 Procedure Preparation of 1,000 tablets each containing 500 mg of the active ingredient:

N-l2-(2-nitro-4,S-dimethoxy-phenyl) ethyll-4-methyl-benzamidine hydrochloride Wheat starch Magnesium aluminum silicate Methylcellulose Stearic acid Colloidal silica Anhydrous ethanol Purified water Procedure EXAMPLE 10 Preparation of 10,000 tablets each containing 50.0 mg of the active ingredient:

Formula: N-methyl-N '-l 2-( 3.4- dimethoxy-phenyl)- ethyll-4-methyl-benzamidine hydrochloride 500.00 g Lactose 1,706.00 g Corn starch 90.00 g Polyethylene glycol 6,000 90.00 g Talcum powder 90.00 g Magnesium stearate 24.00 g Purified water q.s.

All the powders are passed through a screen with an opening of 0.6 mm. Then the drug substance, lactose, talcum, magnesium stearate and half of the starch are mixed in a suitable mixer. The other half of the starch is suspended in 45 ml water and the suspension added to the boiling solution of the polyethylene glycol in ml water. The paste formed is added to the powders which are granulated, if necessary, with an additional amount of water. The granulate is dried overnight at 35, broken on a screen with 1.2 mm openings and compressed into tablets using concave punches with 7.1 mm diameter, uppers bisected.

EXAMPLE ll lnto the solution of 10.0 g N-[2-(2-nitro-4,5- dimethoxy-phenyl)-ethyl]-4-methyl-benzimidoyl chloride in 250 m1 tetrahydrofuran, ammonia is bubbled in while stirring and keeping the temperature at 0. After the mixture turns basic, the precipitate formed is filtered off, dissolved in the minimum amount ofethanol, the solution acidified with ethanolic hydrochloric acid, the precipitate formed filtered off and recrystallized from methanol-ethanol to yield the N-I2-(2-nitro-4,5- dimethoxy-phenyl)-ethyl]4-methyl-benzamidinc hydrochloride, melting at 223-225; it is identical with the compound obtained according to Example 1.

The starting material is prepared as follows: To the solution of 14.2 g 2-(2-nitro-4,5-dimethoxy-phenyl)- ethylamine in 250 ml tetrahydrofuran, cooled to 0, the solution of 5.0 g 4-toluyl chloride in 250 ml tetrahydrofuran is added dropwise while stirring. The precipitate formed is filtered off, the filtrate evaporated in vacuo, the residue triturated with ethyl acetate and recrystallized from ethanol to yield the N-[2-(2-nitro-4,5- dimethoxy-phenyl)-ethyll-4-methyl-benzamide, melting at 169-l71.

The mixture of 10.0 g thereof and 50 ml phosphorus oxychloride is refluxed for 5 hours and evaporated in lized from benzene, to yield the 4-chloro-benzimidine vacuo. The resulting imidoyl chloride is used as such melting at l60-l65. without further purification. In the analogous manner, the following compounds are prepared: EXAMPLE 5 a. N-[l-(3,4-dimethoxyphenyl)-2-n-propyl]-4-meth- T the solutloln f 10 g Y' yl-benzamidine hydrochloride,m.p.2l822()(acphenyltethylamme in 500 ml tetrahydrofuran, 10 g etonimle). N-methyl-4-methyl-benzimidoyl chloride in 120 ml tetl (3,4 dimethoxyphenyl) 2 n buty]] 4 methy| rahydrofuran are added dropwise while stirring at room temperature. After minutes, the mixture is filtered, l0

I tonitrile); the filtrate cooled overnight in the refrigerator, the pre- I c. N-[l-(3,4-dimethoxyphenyl)-2-n-butylI- cipitate formed filtered off and recrystallized from acebenzamidine hl id 33 142 tonitrile, to yield the N-methyl-N-]2-(2-nitro-4,5- thanopacetonitriie); dlmetholfyphenyll'ethyll'4'methylbenzamldlne d. N-[ l-(2-nitro-4,5-dimethoxyphenyl)-2-n-butyl]-4- drochlondfi of the formula methyl-benzamidine hydrochloride, m.p.

CH O C H 3 2 CH 'HCl 1 ll N- CH3 CH3O NO I melting at 198200. l48l52 (toluene);

' 25 e. N-[2-(2-nitro-4,5-dimethoxyphenyl)-n-propyl]-4- EXAMPLE 13 methyl-benzamidine hydrochloride, m.p. l-l38 (methanolacetonitrile);

T of g f l f. N-[2-(3,4-dimethoxyphenyl)-n-butyl]-4-methylamino-n-butane, 6 g 4-chlorobenzamidme and 400 ml benzamidine hydrochloride mtp. l85o l88o toluene is refluxed for four days and evaporated. The

. 3O thanol-acetonitrile resldue is taken up in the minimum amount of ethyl acetate, the solution acidified with hydrogen chloride in EXAMPLE 14 ethyl acetate, the precipitate formed filtered off and re- The mixture f 3 g M3Adimethoxwheny]) ethy|] crystallized from methanol-acetonitrile, to yield the N- 4 h l b hydrochloride, 6 g cMomsu]- l yph nyl)- y l- 35 fonic acid and 500 ml trifluoroacetic acid is refluxed benzamidine hydrochloride of the formula for 3 hours and allowed to stand overnight at room on 0 on -ca C H ll 2 5 NH CH O melting at l 2l97- temperature. It is poured into 1 liter methanol, the so- The starting material is prepared as follows: Through lution evaporated, the residue triturated with diethyl the solution of 10 g 4-chloro-benzonitrile in 50 ml diether and hot water, recrystallized from acetonitrile ethyl ether and 5 ml anhydrous ethanol,hydrogen chloand again from water, to yield the N-[2-(2-sulfo-4,5- ride is bubbled while stirring at 0. After standing overdimethoxyphenyny l- -m y l fl dinfi hynight at room temperature, the mixture is evaporated 50 rfl e f the f rm la on o c H 3 2 uu-c cu -2H 0 C11 0 IS 0 H in vacuo, to yield the 4-chloro-benzimidic acid ethyl ester hydrochloride.

Through the solution of 10 g thereof in 125 ml methanol, ammonia is bubbled for 30 minutes while cooling in an ice bath. The mixture is evaporated in vacuo, the EXAMPLE l5 residue dissolved in the minimum amount of water, the A di g t th h d d ib d i h previous solution made basic with saturated aqueous potassium examples, the following compounds of Formula lll arc hydroxide and extracted with chloroform. The extract prepared from equivalent amounts of the correspondis dried, filtered, evaporated and the residue recrystaling starting materials: R R =R =H, "i=2, 0

melting at 240243. 6O

benzamidine hydrochloride, m.p. l68-l73 (ace- No. R, R1 R8 R9 R Salt mp. C Recr. from I No H OH OCH CH HCl 215 21s cH oH-cH cN Coos: 3 H No OCHJ H CH, HCl 210-212 CH3OHCH3CN 4 N OCH H OCH CH HCl 258-259 do.

benzyl- 5 N02 H oxy OCHJ CH, HCl 237-240 c H oH benzyl- 6 N02 H ocH oxy CH3 HCl 226-229 do.

8 N0 H OCH OCH, CHQCI HCl 213-216 do.

EXAMPLE l6 tered. The filtrate lS concentrated and the precipitate formed recrystallized from diethyl ether-ethanol, to yield the a-(3,4-dimethoxyphenyl)-propionitrile.

The solution of 25 g thereof in 200 ml of tetrahydrofuran is added slowly to the mixture of 260 ml of lmolar borane in tetrahydrofuran and 500 ml of tetrahydro- The mixture of 8.6 g of l-(3,4-dimethoxyphenyl)-2- amino-n-butane, 6.7 g of 4-methylbenzamidine and 300 ml of toluene is refluxed for 4% days and evaporated. The residue is taken up in the minimum amount of ethyl acetate, the solution acidified with hydrogen chloride in ethyl acetate, the precipitate formed tritufura" While Smrmg- Thereupon, the mlxwm rcfluxcd rated with 30 ml of Z-butanone and recrystallized from for 24 hours, Cooled in an ice bath and 50 ml of 4N acetonitrile, to yield the N-[l-(3,4-dimethoxyphenyl)- drochloric acid are added dropwise. It is evaporated Z-n-butyl]-4-methylbenzamidine h d hl id f h under reduced pressure, the residue taken up in water,

the mixture made basic with aqueous potassium hyformula CH 0 C CH 3 H2 l NH-C QCH HCl NH CH O I melting at l68l73. droxide and extracted with chloroform. The extract is washed with water, dried and evaporated, to yield the EXAMPLE 17 2-(3,4-dimethoxyphenyl)-n-propylamine. The mixture of 2.6 g of 2-(3,4-dimethoxyphenyl)-n- We claim: propylamine, 1.7 g of 4-methylbenzamidine and 100 ml of toluene is refluxed for 48 hours and evaporated. The l. A compound of the formula R alk 3 C It 11 NH f d R R R residue is taken up in the minimum amount of ethyl acwherein alk is 1,2-ethylene, l,2-propylene or l,2- etate, the solution acidified with hydrogen chloride in butylene, R is hydrogen, methoxy, chloro, nitro or sulethyl acetate, and the precipitate formed recrystallized fam y each of e and 9 is xy and each 0f m from methanol-acetonitrile, to yield the N-[2-(3,4- and 11 is hydrogen, methyl chloro, 0r 8 Salt t re dimethoxyphenyl)-n-pr0pyl]-4-methylbenzamidine hy- Of a ph rm tically acceptable acid. drochloride of the formula 2. A compound as claimed in claim I, -[2'-(2-nitro- CH O CH- CH 3 2\ NH-C Goa 'HCl Q CH ll 3 NH CH O melting at 210-2l2. 4,5-dimethoxyphenyl)-ethyll-4-methyl-benzamidine or The starting material is prepared as follows: To the a salt thereof of a pharmaceutically acceptable acid.

solution of 35.4 g of 3,4-dimethoxyphenyl-acetonitrile A compound as Claimed in Claim y in 100 ml of dimethylsulfoxide, the solutions of 13.7 ml y-P y y lylof methyl iodide in 30 ml of dimethylsulfoxide and 40 benzamidine or a Salt thereof of Phammaceullcauy g of sodium hydroxide in 40 ml of water are added acceptable aclddropwise at about the same rate while stirring and cool- A Compound as Claimed Clalm -l ing with ice, so that the internal temperature does not dlmethoxyphenyl)'2'n'buty]l'ii'chlom'benzumldmf: or exceed 30. The mixture is stirred at room temperature a salt thereof of a acceptable for 2 hours, 250 ml of water are added and the mixture A compound as Cla'med m Clam 'UT is extracted with 400 ml of benzene and 100 ml of didlmethoxypheny])'2'n'butyll4'methyl'benzamldme ethyl ether. The combined extracts are washed with i gz ggfigg s gg i gg i i l gigl i pfiggiz g g saturated aqueous sodium bicarbonate and sodium dimethoxyphenyl)-npropyl]-4-methyl-benzam|dine or chloride dried and evaporated. The residue is trltull Ira d. rated with diethyl ether-hexane and the solution fila Salt thereof Ofd f l l l dccepmb L cl 

2. A compound as claimed in claim 1, N-(2-(2-nitro-4,5-dimethoxyphenyl)-ethyl)-4-methyl-benzamidine or a salt thereof of a pharmaceutically acceptable acid.
 3. A compound as claimed in claim 1, N-methyl-N''-(2-(3,4-dimethoxy-phenyl)-ethyl)-4-methyl-benzamidine or a salt thereof of a pharamaceutically acceptable acid.
 4. A compound as claimed in claim 1, N-(1-(3,4-dimethoxyphenyl)-2-n-butyl)-4-chloro-benzamidine or a salt thereof of a pharmaceutically acceptable acid.
 5. A compound as claimed in claim 1, N-(1-(3,4-dimethoxyphenyl)-2-n-butyl)-4-methyl-benzamidine or a salt thereof of a pharmaceutically acceptable acid.
 6. A compound as claimed in claim 1, N-(2-(3,4-dimethoxyphenyl)-n-propyl)-4-methyl-benzamidine or a salt thereof of a pharmaceutically acceptable acid. 